MedPath

Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery

Conditions
Breast Cancer
Interventions
Radiation: partial breast irradiation
Registration Number
NCT02617082
Lead Sponsor
Fudan University
Brief Summary

This study is designed to evaluate the feasibility and safety of partial breast irradiation for low risk DCIS after breast-conserving surgery.

Detailed Description

Randomized clinical trials have demonstrated that the recurrence of DCIS is low and most of the recurrence occurs around the tumor bed. Besides, cosmetic outcomes are reported better in partial breast irradiation group compared to whole breast irradiation group. However, whether or not partial breast irradiation is safety in DCIS is still unknown. The purpose of this study is to evaluate the feasibility and safety of partial breast irradiation for low risk DCIS after breast-conserving surgery.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
828
Inclusion Criteria
  • Female
  • 18~65 years old
  • Pathologically confirmed DCIS, low- or intermediate- grade DCIS: (lesions of ≤2.5 cm diameter, resection margins of at least 3 mm, nuclei grade: 1-2), high grade DCIS: (lesions of ≤1 cm diameter, resection margins of at least 3 mm, nuclei grade: 3)
  • Treated with breast conserving surgery
  • Tumor bed is labeled with Titanium clips
  • No malignancy history
  • ECOG score 0~1
  • Written informed consent
Exclusion Criteria
  • DCIS of both breast
  • invasive breast cancer
  • Multicentric disease
  • Patients underwent mastectomy
  • Previous radiation therapy of breast
  • Medical contraindication for radiotherapy
  • Pregnant or nursing
  • suspicious calcification after surgery

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
partial breast irradiationpartial breast irradiation-
Primary Outcome Measures
NameTimeMethod
ipsilateral breast tumor recurrence5 years
Secondary Outcome Measures
NameTimeMethod
occurrence of contralateral breast tumor after PBI5 years
Overall survival5 years
radiation-induced toxicity of breast assessed by CTCAE v4.0baseline, 3 months, 6 months, and every half year to 5 years
Disease free survival5 years
Complicationsbaseline,1,2,3,4,5 years

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath